Conference abstractPublished 7 Jun 2017
Phospholipid-based prodrugs for the treatment of IBD: Drug targeting strategy
Ben-Gurion University of the Negev, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Phospholipase A2 (PLA2) expression/activity is significantly elevated in inflamed intestinal tissue in inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis. PLA2 hydrolyses the sn-2 fatty acyl bond of phospholipids (PL) liberating a fattyacid and a lysophospholipid. By replacing the sn-2 positioned fatty-acid with a drug, PLA2 may be exploited as a prodrug activating enzyme, liberating the free drug from the PL-complex. Therefore, orally delivered PL-based prodrugs will release the free drug at the inflamed sites, effectively targeting the regions of intestinal inflammation. We have utilized a modern computational approach to simulate the PLA2-mediated activation using the candidate drug, and to predict the most appropriate linker length. We have synthesized PL-diclofenac conjugates and shown in-vitro activation of these synthesized conjugates by isolated bee venom PLA2 and conditioned medium from inflamed Caco-2 cell line. We showed that depending on the linker length between the PL and diclofenac, PLA2 could be exploited as the activating enzyme in-vitro, liberating the free diclofenac from the PL complex. We have compared the computational calculations to our experimental data, and obtained excellent correlation between the in-silico predictions and the in-vitro experiments. The proposed research may significantly improve drug therapy in IBD patients, enabling higher efficacy and lower toxicity profiles. Recent Publications 1. A Dahan, S Ben-Shabat, N Cohen, S Keinan, I Kurnikov, A Aponick, E M Zimmermann (2016) Phospholipid-based prodrugs for drug targeting in inflammatory bowel disease: Computational optimization and in-vitro correlation. Curr. Top. Med. Chem. 16: 2543-8. 2. A Dahan, E Zimmermann, S Ben-Shabat (2014) Modern prodrug design for targeted oral drug delivery. Molecules 19: 16489-16505. 3. Wolk, S Epstein, V Ioffe-Dahan, S Ben-Shabat, A Dahan (2013) New targeting strategies in drug therapy of inflammatory bowel disease: Mechanistic approaches and opportunities, Expert Opin. Drug Deliv. 10: 1275-1286. 4. A Dahan, G L Amidon, E M Zimmermann (2010) Drug targeting strategies for the treatment of inflammatory bowel disease: A mechanistic update. Expert Rev. Clin. Immunol. 6: 543-550. 5. A Dahan, R Duvdevani, E Dvir, A Elmann, A Hoffman (2007) A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: In-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J. Control Release 119: 86-93.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Shimon Ben-Shabat”